PALO ALTO, Calif., Feb. 5, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced it has acquired privately-held Mobius
The acquisition of Mobius is consistent with Varian's long-term growth and value creation strategy and broadens its cancer care portfolio. The integration of additional QA tools into the Varian ecosystem will allow advanced QA processes to be more seamlessly combined into treatment workflows. Additionally, Varian also can ensure that QA methods advance at the same time as Varian introduces new treatment techniques.
"Varian has a long history of providing high-quality QA for its products and the treatments they deliver," said Kolleen Kennedy, president of Varian's Oncology Systems business. "Varian places high value on the market-leading Mobius QA products, including Mobius3D and DoseLab, and is dedicated to expanding their global reach. The two companies have similar cultures with deep commitments to enabling quality cancer care for patients around the globe."
The Mobius QA software is in use at over 1000 sites worldwide to ensure patients receive high-quality care. Mobius3D® is a 3D dose verification and IMRT/VMAT treatment delivery QA system. Mobius3D performs 3D dose verification for patient plans, supports verification checks throughout the entire clinical process for IMRT and VMAT, and includes modular staged testing to reinforce the confidence of the medical physicist in the patient plan and treatment delivery. DoseLab® is fast, simple and powerful software for quality assurance of medical linear accelerators.
For more information about the Mobius products that are now part of the Varian cancer care portfolio, visit www.varian.com/mobius.
About Varian Varian is a leader in developing and delivering cancer care solutions, and is focused on creating a world without fear of cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,500 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.
Mark PlungyDirector, Public Relations+1 (650) 424-5630 firstname.lastname@example.org
Investor Relations Contact
J. Michael BruffVice President, Investor Relations+1 (650) 424-5163 email@example.com
View original content:http://www.prnewswire.com/news-releases/varian-acquires-mobius-medical-systems-300592903.html
Subscribe to our Free Newsletters!
Some drugs or therapeutic agents cause undesirable reactions in lungs, known as drug-induced ...
Sleep disorders are collectively known as ''Somnipathy.'' There are over 70 different medically ...View All